SCHEMBL4589689

SCHEMBL4589689

C[SiH](C)OCc1cc(C(C)(C)C)ccc1O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 4/20 0.54
ALDH1A1 P00352 2/20 0.48
HPGD P15428 1/20 0.48
ALOX15 P16050 1/20 0.48
HSD17B10 Q99714 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
KLF10 Q13118 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C19 P33261 1/20 0.46
MAPT P10636 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
GAA P10253 1/20 0.44
PKM P14618 1/20 0.44
RECQL P46063 1/20 0.44
ESR1 P03372 4/20 0.42
ESR2 Q92731 3/20 0.42
TSHR P16473 1/20 0.42
CYP3A4 P08684 2/20 0.40
HIF1A Q16665 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28379813 0.81 CYP2D6 (0.59) CYP2D6ALDH1A1HPGDALOX15HSD17B10
SCHEMBL9347229 0.80 CYP2D6 (0.54) CYP2D6ALDH1A1HPGDALOX15HSD17B10
SCHEMBL8536110 0.80 CYP2D6 (0.36) CYP2D6ALDH1A1HPGDALOX15HSD17B10
SCHEMBL7904051 0.80 CYP2D6 (0.36) CYP2D6ALDH1A1HPGDALOX15HSD17B10
SCHEMBL21002165 0.76 CYP2D6 (0.67) CYP2D6ALDH1A1HPGDALOX15HSD17B10
SCHEMBL51058 0.76 CYP2D6 (0.67) CYP2D6ALDH1A1HPGDALOX15HSD17B10
SCHEMBL7482872 0.76 ALDH1A1 (0.40) CYP2D6ALDH1A1HPGDALOX15HSD17B10
SCHEMBL9435626 0.75 LMNA (0.41) CYP2D6ALDH1A1ALOX15HSD17B10TDP1
SCHEMBL5636034 0.74 KLF10 (0.78) CYP2D6ALDH1A1HPGDALOX15HSD17B10
SCHEMBL1229448 0.74 ESR1 (0.71) CYP2D6ALDH1A1HPGDALOX15HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8946456-B2 Process for the preparation of 2-hydroxy-4-phenyl-3,4-dihydro-2H-chromen-6-yl-methanol and (R)-feso-deacyl CHEMI S.P.A. (IT) 2015-02-03 US disclosed
EP-2580203-B1 PROCESS FOR THE PREPARATION OF 2-HYDROXY-4-PHENYL-3,4-DIHYDRO-2H-CHROMEN-6-YL-METHANOL AND (R)-FESO-DEACYL CHEMI SPA (IT) 2014-08-13 EP disclosed
EP-2580203-A1 PROCESS FOR THE PREPARATION OF 2 -HYDROXY- 4 -PHENYL -3, 4 -DIHYDRO-2H-CHROMEN- 6 -YL -METHANOL AND (R) - FESO - DEACYL Chemi SPA (IT) 2013-04-17 EP disclosed
US-20130079532-A1 PROCESS FOR THE PREPARATION OF 2-HYDROXY-4-PHENYL-3,4-DIHYDRO-2H-CHROMEN-6-YL-METHANOL AND (R)-FESO-DEACYL CHEMI S.P.A. (IT) 2013-03-28 US disclosed
WO-2011154854-A1 PROCESS FOR THE PREPARATION OF 2 -HYDROXY- 4 -PHENYL -3, 4 -DIHYDRO-2H-CHROMEN- 6 -YL -METHANOL AND (R) - FESO - DEACYL CHEMI SPA (IT) 2011-12-15 WO disclosed
US-20080166362-A1 New effector conjugates, process for their production and their pharmaceutical use BERGER MARKUS 2008-07-10 US disclosed
US-7335775-B2 Effector conjugates, process for their production and their pharmaceutical use SCHERING AKTIENGESELLSCHAFT (DE) 2008-02-26 US disclosed
US-20070088060-A1 New effector conjugates, process for their production and their pharmaceutical use BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-04-19 US disclosed
US-7129254-B2 Effector conjugates, process for their production and their pharmaceutical use SCHERING AKTIENGESELLSCHAFT (DE) 2006-10-31 US disclosed
EP-1524979-A2 NEW EFFECTOR CONJUGATES, PROCESS FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE Schering AG (DE) 2005-04-27 EP disclosed
US-20050026971-A1 New effector conjugates, process for their production and their pharmaceutical use SCHERING AG (DE) 2005-02-03 US disclosed
WO-2004012735-A2 NEW EFFECTOR CONJUGATES, PROCESS FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE SCHERING AG (DE) 2004-02-12 WO disclosed
US-5231113-A Skin disorders, immunology or wound healing agents ALLERGAN, INC. (US) 1993-07-27 US disclosed
EP-0337689-B1 TETRALIN ESTERS OF PHENOLS OR BENZOIC ACIDS HAVING RETINOID LIKE ACTIVITY ALLERGAN, INC (US) 1993-03-10 EP disclosed
US-5130335-A Treatment of skin disorders ALLERGAN, INC. (US) 1992-07-14 US disclosed
EP-0337689-A1 Tetralin esters of phenols or benzoic acids having retinoid like activity ALLERGAN, INC (US) 1989-10-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080166362-A1 New effector conjugates, process for their production and their pharmaceutical use EPOR, TIE1, TEK CYP2D6 3306/4885ALDH1A1 1845/4885HPGD 630/4885
US-20050026971-A1 New effector conjugates, process for their production and their pharmaceutical use EPOR, TIE1, TEK CYP2D6 3306/4885ALDH1A1 1845/4885HPGD 630/4885
US-20070088060-A1 New effector conjugates, process for their production and their pharmaceutical use EPOR, TIE1, TEK CYP2D6 3306/4885ALDH1A1 1845/4885HPGD 630/4885
US-20130079532-A1 PROCESS FOR THE PREPARATION OF 2-HYDROXY-4-PHENYL-3,4-DIHYDRO-2H-CHROMEN-6-YL-METHANOL AND (R)-FESO-DEACYL FES, MAOB, BPHL CYP2D6 31/4885ALDH1A1 1823/4885HPGD 729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.